Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hundreds of tables on pelareorep trials, cash-runway projections, and licensing clauses can make a single Oncolytics Biotech annual report 10-K feel impenetrable. If you have ever searched for one line that explains when the next financing might dilute shareholders, you understand the problem. Stock Titan’s AI turns that 300-page document into a concise briefing—Oncolytics Biotech 10-K simplified—so you spend minutes, not hours, finding answers.
The platform monitors EDGAR around the clock, posting Oncolytics Biotech Form 4 insider transactions real-time alongside a clear narrative of why each trade matters. You’ll also see every Oncolytics Biotech quarterly earnings report 10-Q filing, complete with cash-burn trends and trial-cost breakdowns. Want alerts the moment an 8-K appears? Our engine publishes Oncolytics Biotech 8-K material events explained before most investors finish typing the ticker.
Below, you can quickly jump to what professionals ask for most:
- Pelareorep R&D spending and phase-data timelines in the latest Oncolytics Biotech earnings report filing analysis
- Board pay details inside the Oncolytics Biotech proxy statement executive compensation
- Cash-raise clauses hidden in shelf-registration exhibits, surfaced by our AI summaries
- Oncolytics Biotech insider trading Form 4 transactions that reveal management’s conviction
Whether you’re monitoring dilution risk or validating upcoming study catalysts, understanding Oncolytics Biotech SEC documents with AI means the numbers, risks, and opportunities are already highlighted. Explore every filing type—10-K, 10-Q, 8-K, S-3, and more—updated the second they post. Complex biotechnology disclosures have finally met their match.
AirJoule Technologies Corp. (AIRJ) – Form 4 insider transaction
Director Denise Marie Brucia Sterling was granted 25,487 restricted stock units (RSUs) on 07 / 07 / 2025 (Transaction Code “A”). Each RSU represents the right to receive one share of Class A common stock at no exercise cost. The RSUs will vest on the earlier of 07 / 07 / 2026 or the company’s next annual shareholders’ meeting. Following the award, the director beneficially owns 25,487 derivative securities; no common shares were bought or sold.
This filing reflects a routine equity-compensation grant. While it introduces a small potential for dilution when the units convert, it strengthens alignment between board incentives and shareholder interests. No other insider activity or financial data were disclosed.
Cellectar Biosciences (Nasdaq: CLRB) filed Amendment No. 1 to its Form S-1 on 30 June 2025, seeking to register a follow-on public offering of up to 755,667 Class A Units or, at investors’ election, an equal number of Class B Units. Each Class A Unit contains one share of common stock and one five-year common warrant; each Class B Unit substitutes the share with a pre-funded warrant priced at $0.00001 to mitigate ownership-limit issues (4.99% or 9.99% caps).
The filing covers up to 1,556,674 shares issuable upon exercise of pre-funded, common and representative warrants, plus an underwriters’ 45-day over-allotment option for up to 113,350 additional shares and/or warrants. Representative warrants equal to 6% of units sold will also be issued. The assumed public offering price is $7.94, the last closing price on 25 June 2025; final pricing will be set through negotiation with lead underwriter Ladenburg Thalmann.
On 24 June 2025 the company completed a 1-for-30 reverse stock split, leaving authorized share count and par value unchanged. Following the split, Cellectar remains a non-accelerated filer and smaller reporting company. The S-1 reiterates that investing in the securities involves a “high degree of risk,” directing readers to a dedicated Risk Factors section starting on page 17. Proceeds, net of underwriting fees and expenses, are not quantified here and will depend on final pricing and warrant exercise, while the company reserves the right to delay effectiveness until it files a further amendment.
FAQ
What is the current stock price of Oncolytics Biotech (ONCY)?
What is the market cap of Oncolytics Biotech (ONCY)?
What is the core focus of Oncolytics Biotech Inc?
How does pelareorep work in cancer treatment?
Which cancer types are being targeted by the company's clinical trials?
What stage is Oncolytics Biotech Inc's clinical development program in?
How does the company ensure the quality of its product development?
What differentiates Oncolytics from other oncology biotech companies?
How does Oncolytics engage with regulatory authorities?
Where can investors and analysts find more information about the company's progress?
